cilostazol has been researched along with Renal Insufficiency in 4 studies
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol (CTZ) is a phosphodiesterase Ш inhibitor, it is a potent vasodilator and antiplatelet drug." | 5.72 | Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis. ( Khattab, MI; Khorshid, NE; Saeed, ZM; Salem, AE, 2022) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| "Noncompartmental pharmacokinetic parameters were determined for each study participant." | 2.69 | Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. ( Bramer, SL; Forbes, WP; Mallikaarjun, S, 1999) |
| "Cilostazol (CTZ) is a phosphodiesterase Ш inhibitor, it is a potent vasodilator and antiplatelet drug." | 1.72 | Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis. ( Khattab, MI; Khorshid, NE; Saeed, ZM; Salem, AE, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 1 |
| Manolis, AS | 1 |
| Saeed, ZM | 1 |
| Khattab, MI | 1 |
| Khorshid, NE | 1 |
| Salem, AE | 1 |
| Funabiki, K | 1 |
| Masuoka, H | 1 |
| Shimizu, H | 1 |
| Emi, Y | 1 |
| Mori, T | 1 |
| Ito, M | 1 |
| Nakano, T | 1 |
| Mallikaarjun, S | 1 |
| Forbes, WP | 1 |
| Bramer, SL | 1 |
2 reviews available for cilostazol and Renal Insufficiency
| Article | Year |
|---|---|
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature.
Topics: Aged; Blue Toe Syndrome; Cardiac Catheterization; Cholecystitis; Cilostazol; Coronary Angiography; C | 2003 |
1 trial available for cilostazol and Renal Insufficiency
| Article | Year |
|---|---|
Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Topics: Administration, Oral; Analysis of Variance; Area Under Curve; Chromatography, High Pressure Liquid; | 1999 |
1 other study available for cilostazol and Renal Insufficiency
| Article | Year |
|---|---|
Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis.
Topics: Amikacin; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Cilostazol; Ellagic Acid; In | 2022 |